Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MZE782 in adults with phenylketonuria
2026-525622-37-01Phase 2Authorised
- Sponsor
- Maze Therapeutics
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of MZE782 in phenylketonuria (PKU) (4 arms), sponsored by Maze Therapeutics. Planned start Oct 2026; status: authorised.
02
Drugs
MZE782
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on 2026-525622-37-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525622-37-01.